Richard Pestell
CEO and Founder in Fort Lauderdale, FL, United States
Richard Pestell began his medical journey at the University of Western Australia, where he graduated at the top of his class and earned an M.B., B.S. His early training continued at the Royal Perth Hospital and St Vincent's Hospital, Sydney, where he worked as a physician in training. Across Internal Medicine and residency, he gained experience in oncology, endocrinology, hematology, cardiology, and transplant medicine, which shaped his approach to patient-centered care and research.
He pursued cancer biology through advanced research, culminating in a Ph.D. from the University of Melbourne at the Howard Florey Institute, specializing in oncogene regulation of gene transcription. National scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award, supported his academic progress. These achievements brought him to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow.
Richard continued his academic career at Northwestern University and later at the Albert Einstein College of Medicine. He became a Professor, Chair of the Division of Endocrine-Dependent Tumor Biology, and Co-Director of major cancer research programs. He also held positions at multiple hospitals in New York, which helped him remain involved in patient care and medical education while building research programs focused on cancer biology.
Richard Pestell’s research contributed to the scientific foundation for cancer therapeutics and clinical translation. His research on cyclin D1 was cited in the seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. His work on CCR5 provided the scientific framework for current oncology clinical trials with CCR5 inhibitors. His scholarly record includes over 700 publications, more than 110,000 citations, an h-index of 162, and extensive invitations to give invited lectures worldwide.
In 2002, he became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University. He also served as Chair of the Department of Oncology and as Associate Vice President at Georgetown University Medical Center. In these roles, he was responsible for research, clinical operations, and faculty development, and he participated in institutional restructuring and growth. He strengthened research programs, supported community partnerships, and expanded clinical services across Georgetown and MedStar systems.
Richard took on additional leadership roles in 2005 as the Director of the Sidney Kimmel Cancer Center, Chair of the Department of Cancer Biology, and head of the Oncology Service Line at Thomas Jefferson University. He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led efforts in clinical care, research infrastructure, regional expansion, and team building. During his tenure, the cancer center rose from 64th to 17th.
Richard Pestell held academic roles outside the US and contributed to research, education, and outreach initiatives. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. He served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions.
Richard has served with prominent scientific bodies, including the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion, the Eric Susman Prize in Medicine, and his 2019 appointment as an Officer of the Order of Australia. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors, plus more than 80 million dollars as a principal investigator on NIH research grants.
Books He Wrote or Contributed To:
Molecular Endocrinology: Basic Concepts and Clinical Correlations
Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer
Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies
Molecular Targeting and Signal Transduction (Cancer Treatment and Research)